Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press10710.17650/2220-3478-2013-0-1-43-53ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯENDOVASCULAR TREATMENT OF LOCALLY-ADVANCED RECTAL CARCINOMA CONSIDERING SPECIFIC FEATURES OF BLOOD SUPPLY OF RECTUM (THE REVIEW OF LITERATURE AND OWN OBSERVATIONS)ПАНИТУМУМАБ (ВЕКТИБИКС) В ТЕРАПИИ ХИМИОРЕЗИСТЕНТНОГО МЕТАСТАТИЧЕСКОГО РАКА ТОЛСТОЙ КИШКИ. РЕТРОСПЕКТИВНЫЙ АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ В ОТДЕЛЕНИИ ХИМИОТЕРАПИИBrederV. V.БредерВ. В.
Russian Federation
vbreder@yandex.ruGorbunovaV. A.ГорбуноваВ. А.
Russian Federation
vbreder@yandex.ruOrelN. F.ОрелН. Ф.
Russian Federation
vbreder@yandex.ruOrlovaK. V.ОрловаК. В.
Russian Federation
vbreder@yandex.ruKuzminovA. E.КузьминовА. Е.
Russian Federation
vbreder@yandex.ruБорисоваT. A.БорисоваТ. А.
Russian Federation
vbreder@yandex.ruBisovskayaYu. V.БисовскаяЮ. В.
Russian Federation
vbreder@yandex.ruGagarinI. N.ГагаринИ. Н.
Russian Federation
vbreder@yandex.ruMazurenkoN. N.МазуренкоН. Н.
Russian Federation
vbreder@yandex.ruMochalnikovaV. V.МочальниковаВ. В.
Russian Federation
vbreder@yandex.ruKholyavkaE. N.ХолявкаЕ. Н.
Russian Federation
vbreder@yandex.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва280220132143530203201502032015Copyright ©; 2013, Breder V.V., Gorbunova V.A., Orel N.F., Orlova K.V., Kuzminov A.E., Борисова T.A., Bisovskaya Y.V., Gagarin I.N., Mazurenko N.N., Mochalnikova V.V., Kholyavka E.N.Copyright ©; 2013, Бредер В.В., Горбунова В.А., Орел Н.Ф., Орлова К.В., Кузьминов А.Е., Борисова Т.А., Бисовская Ю.В., Гагарин И.Н., Мазуренко Н.Н., Мочальникова В.В., Холявка Е.Н.2013Breder V.V., Gorbunova V.A., Orel N.F., Orlova K.V., Kuzminov A.E., Борисова T.A., Bisovskaya Y.V., Gagarin I.N., Mazurenko N.N., Mochalnikova V.V., Kholyavka E.N.Бредер В.В., Горбунова В.А., Орел Н.Ф., Орлова К.В., Кузьминов А.Е., Борисова Т.А., Бисовская Ю.В., Гагарин И.Н., Мазуренко Н.Н., Мочальникова В.В., Холявка Е.Н.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/107

The review literature regarding endovascular interventions for rectal cancer treatment is presented. The results of treatment of loco-regional rectal carcinoma by with the help of endovascular selective lipiodol oil chemoembolization of the rectal arteries, and also the data concerning features of blood supply of rectum, received by selective angiography are presented. The results confirm expediency of endovascular methods in treatment of rectal cancer considering specific features of blood supply of rectum.

Представлены результаты лечения панитумумабом (вектибиксом) химиорефрактерного метастатического рака толстой кишки без мутации гена KRAS («дикий» тип) в отделении химиотерапии ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН. Высокая непосредственная эффективность (24,3 %) панитумумаба сопровождалась продолжительной выживаемостью без прогрессирования (медиана 4,71 мес), общая выживаемость в группе – 11,5 мес. При хорошей и предсказуемой переносимости лечения специфическая кожная токсичность ( II степени) препарата – значимый фактор прогноза эффективности вектибикса.

rectal carcinomaendovascular treatment and surgeryintra-arterial selective oily chemoembolizationRACHEL procedureметастатический колоректальный ракхимиорезистентностьтаргетная терапияпанитумумаб1. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Под ред. М.И. Давыдова и Е.М. Аксель. Вестник РОНЦ им. Н.Н. Блохина РАМН 2011;22;3(85), прил. 1.Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Под ред. М.И. Давыдова и Е.М. Аксель. Вестник РОНЦ им. Н.Н. Блохина РАМН 2011;22;3(85), прил. 1.2. Scheithauer W., Rosen H., Kornek G.V. et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752–5.Scheithauer W., Rosen H., Kornek G.V. et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752–5.3. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904–11.Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904–11.4. Grothey A., Sargent D., Goldberg R.M., Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–14.Grothey A., Sargent D., Goldberg R.M., Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–14.5. Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441–42.Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441–42.6. Dienstmann R., Vilar E., Tabernero J. et al. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J 2011;17(2):114–26.Dienstmann R., Vilar E., Tabernero J. et al. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J 2011;17(2):114–26.7. Weitz J., Koch M., Debus J. et al. Colorectal cancer. Lancet 2005;365:153–65.Weitz J., Koch M., Debus J. et al. Colorectal cancer. Lancet 2005;365:153–65.8. Gunderson L., Jessup J., Sargent D. et al. Revised TN categorization for colon cancerbased on national survival outcome. J Clin Oncol 2010;28(2):264–71.Gunderson L., Jessup J., Sargent D. et al. Revised TN categorization for colon cancerbased on national survival outcome. J Clin Oncol 2010;28(2):264–71.9. Grothey A., Sobrero A.F., Siena S. et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 2012;30(suppl 4; abstr LBA385).Grothey A., Sobrero A.F., Siena S. et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 2012;30(suppl 4; abstr LBA385).10. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12(8):5268–72.Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12(8):5268–72.11. You B., Chen E.X. Anti-EGFR monoclonal antibodies for the treatment of colorectal cancer: development of cetuximab and panitumumab. Clin Pharmacol 2012;52(2):128–55.You B., Chen E.X. Anti-EGFR monoclonal antibodies for the treatment of colorectal cancer: development of cetuximab and panitumumab. Clin Pharmacol 2012;52(2):128–55.12. NCI CTC v.2 National Cancer Institute. Common toxicity criteria (ver.2). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv2nom-4-30-99-fi nal3.pdf (accessed Aug 25, 2011).NCI CTC v.2 National Cancer Institute. Common toxicity criteria (ver.2). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv2nom-4-30-99-fi nal3.pdf (accessed Aug 25, 2011).13. Köhne C.H., Cunningham D., Di C.F. et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308–17.Köhne C.H., Cunningham D., Di C.F. et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308–17.14. Amado R.G., Wolf M., Peeters M. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.Amado R.G., Wolf M., Peeters M. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.15. Karapetis C.S., Khambata-Ford S., Jonker D.J. et al. Kras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65.Karapetis C.S., Khambata-Ford S., Jonker D.J. et al. Kras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65.16. Mekenkamp L.J.M., Heesterbeek K.J., Koopman M. et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 2012;48(4):501–9. doi:10.1016/j.ejca.2011.12.004Mekenkamp L.J.M., Heesterbeek K.J., Koopman M. et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 2012;48(4):501–9. doi:10.1016/j.ejca.2011.12.00417. Tol J., Nagtegaal I.D., Punt C.J. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98–9.Tol J., Nagtegaal I.D., Punt C.J. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98–9.18. Di Nicolantonio F., Martini M., Molinari F. et al. BRAF wild-type is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705–12.Di Nicolantonio F., Martini M., Molinari F. et al. BRAF wild-type is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705–12.19. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F. et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643–8.Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F. et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643–8.20. Chibaudel B., Bonnetain F., Tournigand C. et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR Study. The Oncologist 2011;16:1228–38.Chibaudel B., Bonnetain F., Tournigand C. et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR Study. The Oncologist 2011;16:1228–38.21. Van Cutsem E., Peeters M., Siena S. et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. J Clin Oncol 2007;25(13):1658–64.Van Cutsem E., Peeters M., Siena S. et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. J Clin Oncol 2007;25(13):1658–64.22. Misale S., Yaeger R., Hobor S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486(7404):532–6. doi:10.1038/nature11156.Misale S., Yaeger R., Hobor S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486(7404):532–6. doi:10.1038/nature11156.23. Grothey A. EGFR antibodies in colorectal cancer: where do they belong? J Clin Oncol 2010;28(31):4668–70. doi 10.1200/JCO.2010.29.3707.Grothey A. EGFR antibodies in colorectal cancer: where do they belong? J Clin Oncol 2010;28(31):4668–70. doi 10.1200/JCO.2010.29.3707.24. Sobrero A.F., Maurel J., Fehrenbacher L. et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311–2319.Sobrero A.F., Maurel J., Fehrenbacher L. et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311–2319.25. Van Cutsem E., Peeters M., Siena S. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients withchemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–64.Van Cutsem E., Peeters M., Siena S. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients withchemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–64.26. Ducreux M., Malka D., Mendiboure J. et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011;12:1032–44.Ducreux M., Malka D., Mendiboure J. et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011;12:1032–44.27. Adams R., Meade A., Seymour M. et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12:642–53.Adams R., Meade A., Seymour M. et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12:642–53.28. Douillard J.Y., Siena S., Cassidy J. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, andoxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010;28:4697–705.Douillard J.Y., Siena S., Cassidy J. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, andoxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010;28:4697–705.29. Peeters M., Price T.J., Cervantes A. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–13.Peeters M., Price T.J., Cervantes A. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–13.30. Folprecht G., Gruenberger T., Bechstein W.O. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38–47.Folprecht G., Gruenberger T., Bechstein W.O. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38–47.